Topic: diabetes

A team of Stanford University scientists has found a way to direct a regenerative diabetes medicine to the right cells more precisely.

With the diabetes project moving to within a few years of the clinic, Novo is stepping up its interest in stem cell therapies more broadly. 

The midphase Type 2 diabetes candidate slots into the pipeline of Roivant’s newly minted cardiometabolic disease startup Metavant.

The initiative will provide certain UnitedHealth members with Dexcom’s CGM technology and personalized coaching to help manage their diabetes.

The Minneapolis-based medtech firm is aiming to improve glucose control in diabetics by ablating nerves linked to metabolic organs.

Fractyl plans to use the funds to develop its water-filled balloon device, Revita DMR.

Here's Wednesday's medtech news of note.

KalVista has been looking for a big pharma partner for its plasma kallikrein inhibitors, and just had its wish fulfilled by Merck & Co.

Lexicon now has data from two phase 3 trials showing the effect of the SGLT1-SGLT2 inhibitor on A1C in patients with Type 1 diabetes is sustained over 52 weeks.